Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Genocea Biosciences Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Genocea Biosciences Inc market cap is $100.00.
What is the 52-week high for Genocea Biosciences Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Genocea Biosciences Inc 52 week high is $0.0005 as of October 10, 2025.
What is the 52-week low for Genocea Biosciences Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Genocea Biosciences Inc 52 week low is $0.00 as of October 10, 2025.
What is the 50-day moving average of Genocea Biosciences Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Genocea Biosciences Inc 50-day moving average is $0.00.